MHMiguel Hernandez-Bronchud

Miguel Hernandez-Bronchud

*This is an algorithmically generated author record based on publicly available information.

Miguel Hernandez-Bronchud has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial

    by Hope S. Rugo, Eduardo J. Pennella, Unmesh Gopalakrishnan, Miguel Hernandez-Bronchud, Jay Herson, Hans Friedrich Koch, Subramanian Loganathan, Sarika Deodhar, Ashwani Marwah, Alexey Manikhas, et al.


  • Do locally advanced and metastatic human epithelial cancers evolve in ‘placental/decidual-like microenvironments’?

    by M. Hernández-Bronchud

    Successful tumor microenvironments eventually kill the host. They are not only meant to nourish and protect tumor development, but to give them the right “soil” for perpetual malignant properties such as tissue invasion and metastasis. This can only be achieved if cancers avoid immune vigilance. A similar situation occurs in mammalian placental pregnancy but feto-maternal tolerance is required for a correct physiological process only until birth. Once a cancer microenvironment has acquired the genetic and epigenetic “placental immune editing switches” (PIES) phenotype, it seems likely that it will keep them “available”, whenever needed, for the rest of its development, because it gives cellular clones a competitive advantage to pass unnoticed by the host’s immune system. This allows primary cancers and their metastasis to continue growing in spite of new and changing antigenic landscapes.


  • Open Access

    Are aggressive epithelial cancers ‘a disease’ of Eutherian mammals?

    by Miguel H Bronchud

    Ecancermedicalscience is the peer-reviewed open access cancer journal founded by the European Institute of Oncology in Milan. We consider articles on all aspects of research relating to cancer, including molecular biology, genetics, pathophysiology, epide


  • Open Access

    Epigenetic changes found in uterine decidual and placental tissues can also be found in the breast cancer microenvironment of the same unique patient: description and potential interpretations

    by Miguel H. Bronchud, Francesc Tresserra, Bernat Serra Zantop

    // <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Miguel H. Bronchud1, Francesc Tresserra2 and Bernat Serra Zantop3 1Institut Bellmunt Oncologia, Hospital Universitari Dexeus, Grupo Quiron Salud, Barcelona, 08028 Spain 2Servicio de Anatomía Patológica y Citología, Hospital Universitari Dexeus, Grupo Quiron Salud, Barcelona, 08028 Spain 3Servicio de Ginecología, Obstetricia y Reproducción, Hospital Universitari Dexeus, Grupo Quiron Salud, Barcelona, 08028 Spain Correspondence to: Miguel H. Bronchud, email: mhbronchud@gmail.com Keywords: materno-fetal tolerance; cancer microenvironment; placental microenvironment; immune vigilance; carcinogenesis Received: April 21, 2017 Accepted: December 02, 2017 Published: December 19, 2017 ABSTRACT Microenvironmental properties are thought to be responsible for feto-maternal tolerance. Speculatively, ectopic expression of placental gene programs might also be related to cancer cells’ ability to escape from immune vigilance mechanisms during carcinogenesis and cancer progression. Recently, we published the first human genomic evidence of similar immune related gene expression profiles in both placenta (placenta and decidual tissue) and cancer (both primary and metastatic) in the same patient with lymph-node positive breast carcinoma during pregnancy. Here we report the first epigenomic analysis of these tissue samples and describe their main findings, with respect to immune related genes regulation (over or under expressed) in cancer cells with regards placental tissues. We confirm significant similarities, and hierarchical clustering (both unsupervised and supervised), in CpG island methylation patterns between decidual/placental and cancer microenvironments, which cannot be easily explained by simple models or unique pathways. Several different cell types are probably involved in these complex immune regulation mechanisms. Cancers may somehow “hijack” gene programs evolved over millions of years to allow for feto-maternal tolerance in placental mammals in order to escape from immune vigilance and spread locally or to distant sites.


  • Open Access

    Placental immune editing switch (PIES): learning about immunomodulatory pathways from a unique case report

    by Miguel H. Bronchud, Francesc Tresserra, Wenjie Xu, Sarah Warren, Maite Cusido, Bernat Zantop, Ana Claudia Zenclussen, Alessandra Cesano

    The hypothesis of this work is that, in order to escape the natural immune surveillance mechanisms, cancer cells and the surrounding microenvironment might express ectopically genes that are physiologically present in the placenta to mediate fetal immune-tolerance. These natural “placental immune-editing switch” mechanisms (PIES) may represent the result of millions of years of mammalian evolution developed to allow materno-fetal tolerance. Here, we introduce genes of the immune regulatory pathways that are either similarly over- or under-expressed in tumor vs normal tissue. Our analysis was carried out in primary breast cancer with metastatic homolateral axillary lymph nodes as well as placenta tissue (both uterine decidual tissue and term placenta tissue) from a pregnant woman. Gene expression profiling of paired non-self and self tissues (i.e. placenta/uterus; breast cancer/normal breast tissue; metastatic lymphnode/normal lymphnode tissue) was performed using the PanCancer Immune gene panel, a 770 Nanostring gene expression panel. Our findings reveal overlapping in specific immune gene expression in placenta and cancer tissue, suggesting that these genes might play an important role in maintaining immune tolerance both physiologically (in the placenta) and pathologically (in the cancer setting).